ReviewFrontiers in pharmacology2022
Tocilizumab and COVID-19: Timing of Administration and Efficacy.
Review in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 56 citations in OpenAlex.
- Observational
- Novel soluble bazedoxifene formulation gains antiproliferative and migrastatic effect in squamous cell carcinoma cells.Scientific reports · 2026Article
- Current Insights into Clinical, Molecular, and Therapeutic Approaches to Acute Respiratory Distress Syndrome.Medical sciences (Basel, Switzerland) · 2026Review
- COVID-19 immunopathological features for the prediction and prevention of future emerging respiratory viral infections.Computational and structural biotechnology journal · 2026Article
- Dengue and severe dengue.Clinical microbiology reviews · 2025Review
- Drug repositioning as a promising approach for the eradication of emerging and re-emerging viral agents.Molecular diversity · 2025Review
- The Clinical Value of Inflammatory Indicators at the Time of Secondary Infection After Treatment With Tocilizumab: A Cross-Sectional Study.Health science reports · 2025Article
- Chronic Obstructive Pulmonary Disease and COVID-19: The Impact of Hematological Biomarkers on Disease Severity and Outcomes.Journal of clinical medicine · 2025Review
- The impact of tocilizumab treatment on the severity of inflammation and survival rates in sepsis is significantly influence by the timing of administration.Inflammopharmacology · 2025Article
- The predictive value of the LDH-albumin ratio on poor clinical course and mortality in COVID-19 patients: A single-center study.Medicine · 2025Observational
- Tocilizumab and IVIG experience during the service follow-up in patients with severe COVID-19 pneumonia.Revista do Instituto de Medicina Tropical de Sao Paulo · 2025Article
- Development of a short-term prognostic model for hepatitis B-related acute-on-chronic liver failure in a dual-center cohort.Frontiers in medicine · 2025Article
- Machine learning-based approach to guide the choice between baricitinib and tocilizumab in critical COVID-19 pneumonia treatment: a retrospective cohort study.Frontiers in medicine · 2025Article
- Retinal and Corneal OCT Results of Patients Hospitalized and Treated in the Acute Phase of COVID-19.Journal of clinical medicine · 2024Article
- Postacute Sequelae of COVID (PASC or Long COVID): An Evidenced-Based Approach.Open forum infectious diseases · 2024Review
- Frontiers and hotspots evolution in cytokine storm: A bibliometric analysis from 2004 to 2022.Heliyon · 2024Article
- Correlation between Serum Biomarkers and Lung Ultrasound in COVID-19: An Observational Study.Diagnostics (Basel, Switzerland) · 2024Article
- Neutrophils and the Systemic Inflammatory Response Syndrome (SIRS).International journal of molecular sciences · 2023Review
- Long-COVID fatigue is not predicted by pre-pandemic plasma IL-6 levels in mild COVID-19.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2023Article
- Different cytokine and chemokine profiles in hospitalized patients with COVID-19 during the first and second outbreaks from Argentina show no association with clinical comorbidities.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Elevated concentrations of interleukin-6 have been demonstrated to be an important key factor in COVID-19 host immune impairment. It represents an important prognostic factor of harm associated with COVID-19 infection by stimulating a vigorous proinflammatory response, leading to the so-called "cytokine storm". Therefore, immunomodulatory interventions targeting interleukin-6 receptor antagonism have been investigated as potential treatments to counterbalance the host immune dysregulation and to support the advantageous effects of corticosteroids. Tocilizumab is a recombinant humanized monoclonal antibody that has gained much interest during the COVID-19 pandemic as an interleukin-6 receptor antagonist. Various early observational studies have reported beneficial effects of tocilizumab. Moreover, consequent randomized controlled trials have subsequently shown significant positive results about tocilizumab efficacy and safety, focusing on outcomes like mortality, risk of intensive care unit admission, and the need for mechanical ventilation, while others presented conflicting findings. In this review, we first described the pathophysiology of COVID-19 infection while highlighting the role of interleukin-6. Furthermore, we also discussed the non-conclusive evidence about tocilizumab to be used as the standard of care therapy for all patients with COVID-19 pneumonia, as well as its beneficial effects in selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.